What is Retaane used for?

Retaane is indicated for Exudative age-related macular degeneration.

What development phase is Retaane in?

Retaane is FDA-approved (marketed).

What is the generic name of Retaane?

anecortave is the generic (nonproprietary) name of Retaane.

Last reviewed 2026-04-20 · How we verify

Retaane (anecortave)

FDA-approved active Quality 17/100

At a glance

Generic name	anecortave
Drug class	anecortave
Target	Plasminogen activator inhibitor 1
Therapeutic area	Ophthalmology
Phase	FDA-approved

Approved indications

Exudative age-related macular degeneration

Common side effects

No common side effects on file.

Key clinical trials

Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients (NA)
Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD (PHASE3)
Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD (PHASE3)
A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension (PHASE2)
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD (PHASE3)
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD) (PHASE3)
Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension (PHASE2,PHASE3)
Anecortave Acetate Risk-Reduction Trial (AART) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Retaane CI brief — competitive landscape report
Retaane updates RSS · CI watch RSS
portfolio CI